E. David Crawford, MD, Editor-in-Chief
LEARNING CENTERS
LATEST CONTENT
Discussion of FDA Industry Guidelines for Developing Gonadotropin-Releasing Hormone Analogues for Advanced Prostate Cancer E. David Crawford, MD, and Celestia Higano, MD, discuss the U.S. Food and Drug Administration's announcement of the availability of a draft...
Jason A. Efstathiou, MD, DPhil, emphasizes the need for continued clinical trials to refine therapy options for high-risk and locally advanced prostate cancer patients. He reviews six major considerations regarding the current state of external beam radiation therapy (EBRT) for the treatment of high-risk disease.
Daniel P. Petrylak, MD, analyzes the current status of immunotherapy for prostate cancer, reviewing available options, emerging combination therapies, and immunotherapy clinical trials. He also emphasizes the impact of PD-L1 expression, microsatellite instability, and other mutations in prostate cancer on patient responses to immunotherapy.
Bladder Cancer Journal Vol. 5 Issue 2Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer The fibroblast growth factor receptor 3 (FGFR3) plays critical roles in driving oncogenesis of a subset of patients with urothelial carcinomas (UC)....
This interview, "Dr. Alicia Morgans: Putting Chemo Into Perspective," is provided by Grand Rounds in Urology's content partner, Prostatepedia. Dr. Alicia Morgans is a medical oncologist at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in...
Alan W. Shindel, MD, MAS, discusses the current treatment of erectile dysfunction (ED) with PDE5 inhibitors, as well as the limitations of the currently available drugs for ED patients. He also reviews a number of potential targets for novel ED treatments, including nitric oxide, soluble guanylate cyclase, the RhoA/Rho Kinase/ROCK pathway, and the Sonic Hedgehog protein.
Timothy K. Byler, MD, discusses the significant quality of life impact associated with nocturia, as well as underlying diseases and causative factors. He then reviews findings on the epidemiology of nocturia and its prevalence in women in the United States.
